The Emerging Cancer Vaccine Market, 2nd Edition

Below is the list of sections extracted directly from the report. Please note this list has been standardized and may not match the Table of Contents.

• Executive Summary
  • INTRODUCTION
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH OF THE MARKET
  • ISSUES AND TRENDS AFFECTING MARKET
  • COMPETITIVE ANALYSIS
  • PROFILES
• Introduction
  • HISTORY AND GROWTH OF THE CANCER TREATMENT MARKET
  • TYPES OF VACCINES
    • Antigen/Adjuvant Vaccines
    • Whole Cell Tumor Vaccines
    • Dendritic Cell (DC) Vaccines
    • Viral Vectors and DNA Vaccines
    • Idiotype Vaccines
    • Types of Therapeutic Vaccines
  • INDUSTRY STRUCTURE
  • DEMOGRAPHICS AND STATISTICS
    • (Table) Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2005 and 2020 Cancer Incidence (in thousands)
    • (Table) Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2005 and 2020
    • (Table) Total Cancer Incidence by Sex and Country, 2006 Estimates
    • (Table) Estimated Cancer Incidence by World Region and Type of Cancer Cancer Incidence by World Region (in thousands)
    • (Table) World Population by Selected Geographical Region, 2006-2050
    • (Table) Estimated World Population by Age and Geographical Region, 2006
    • (Table) Life Expectancy at Birth by Selected Countries, Projected 2006
    • (Table) United States Life Expectancy at Birth, 1990 and 2000; Projections, 2006 and 2010
    • (Table) United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2002
• Cervical Cancer Vaccines
  • OVERVIEW
    • (Table) Estimated U.S. and World Incidence and Mortality of Cervical Cancer
  • VACCINES PRODUCTS
    • On the Market
    • In Development
      • (Table) Cervical Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Cervical Cancer Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Projected Cervical Cancer Vaccine Market in Comparison to Traditional Therapeutics, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Cervical Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Colon/Rectal Cancer Vaccines
  • OVERVIEW
    • (Table) Estimated U.S. and World Incidence and Mortality of Colon/Rectal Cancer
  • VACCINE PRODUCTS
    • On the Market
    • In Development
      • (Table) Colon/Rectal Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Colon/Rectal Cancer Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Colon/Rectal Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Colon/Rectal Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Lung Cancer Vaccines
  • OVERVIEW
    • (Table) Types of Primary Lung Cancer, Risk Factors, Percent of Cases
    • (Table) Cancer Vaccines: Estimated World Incidence and Mortality of Lung Cancer (thousands)
  • VACCINE PRODUCTS IN DEVELOPMENT
    • Stimuvax
    • ICN-101
    • GV-1001
    • Ep2101
    • Oncophage
    • PanVac + Taxotere
    • MAGE-3 Peptide
    • INGN 225
    • TG 4010
    • L-VAX
    • ALT-110
    • CEA-TriCom
    • DC Vax
    • Lapuleucel-T
    • L523S
      • (Table) Lung Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Lung Cancer Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Lung Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Lung Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Lymphoma Vaccines
  • OVERVIEW
    • (Table) Classification of Non-Hodgkin's Lymphomas
    • (Table) Estimated U.S. and World Incidence and Mortality of Lymphoma
  • VACCINES IN DEVELOPMENT
    • MyVax
    • BiovaxID
    • FavId
    • Oncophage
    • TG4010
    • FAV-201
    • Non-Hodgkin's Lymphoma Vaccine
    • BGLP40 Vaccine
      • (Table) Lymphoma Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Lymphoma Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Lymphoma Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Lymphoma Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Melanoma Vaccines
  • OVERVIEW
    • (Table) Malignant Conditions of the Skin
    • (Table) Estimated U.S. and World Incidence and Mortality of Melanoma
  • VACCINES ON THE MARKET
  • VACCINES IN DEVELOPMENT
    • M-VAX
    • GMK
    • Allovectin-7
    • MDX-010/MDX-1379
    • Oncophage
    • Canvaxin
    • Melacine
    • Triple Peptide Vaccine
    • MART-1/Melan-A
    • MAGE-3 Peptide
    • TriCom
    • Tyrosinase Peptide
    • Uvidem
    • Melan-A/MART-1 and gp100
    • ALVAC -CEA/B7.1
    • MDX-1106/ONO-4538
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) Melanoma Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
    • (Table) The World Market for Melanoma Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Melanoma Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Melanoma Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Prostate Cancer Vaccines
  • OVERVIEW
    • (Table) Estimated U.S and World Incidence and Mortality of Prostate Cancer
  • VACCINES IN DEVELOPMENT
    • Provenge
    • DC Vax-Prostate
    • GVAX
    • Stimuvax
    • GnRH Pharmaccine Therapeutic Vaccine
    • IGN-101
    • Pentrix
    • PROSTVAC-VF
    • Telomerase Cancer Vaccine
    • TG4010
    • Norelin
    • PSMA RS Protein Vaccine
    • Luteinizing Hormone Releasing Hormone
    • ALT-110
      • (Table) Prostate Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Prostate Cancer Vaccines Revenues and Growth Rate 2007-2012
    • (Table) The Prostate Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) The Prostate Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
• Various Cancer Vaccines
  • OVERVIEW
    • Bladder Cancer
    • Breast Cancer
    • Stomach Cancer
    • Liver Cancer
    • Pancreatic Cancer
    • Kidney Cancer
    • Leukemia
      • (Table) Types of Leukemia (Incidence, Age of Onset, Clinical Manifestations)
    • Multiple Myeloma
    • Neuroblastoma
    • Ovarian Cancer
    • Sarcoma
      • (Table) Estimated U.S. World Incidence and Mortality of Various Cancers (Bladder, Breast, Kidney, Leukemia, Liver, Neuroblastoma, Ovarian, Pancreatic, Stomach)
  • VACCINES ON THE MARKET
    • BCG Therapy (OncoTICE-Organon Teknika; Immucyst-Sanofi Pasteur; Pacis-Shire Pharmaceuticals)
  • VACCINES IN DEVELOPMENT
    • Oncophage
    • Insegia
    • Avicine
    • MyVax
    • PANVAC-VF
    • Theratope
    • Bexidem
    • AG-858
    • DC Vax
    • GVAX
    • IGN-101
    • O-VAX Autologous Cell Vaccine
    • PX 104.1
    • TroVAX
    • Dendritic Cell/Tumor Cell Fusion Cancer Vaccine
    • INGN 225
    • ALT-110
    • DNA Cancer Vaccine
    • GV 1001
    • Lapuleucel-T
    • Lovaxin C
    • MDX-1307
    • Telomerase
      • (Table) Various Cancer Vaccines in the Pipeline (Product, Developer, Phase, Cancer Type, Earliest Approval Date)
  • MARKET AND PRODUCT LAUNCH FORECASTS
    • (Table) The World Market for Other Cancer Vaccines Revenues and Growth Rate 2007-2012
    • (Table) Figure 9-3 The Emerging Various Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • POTENTIAL COMPETITORS AND ANALYSIS, 2012
    • (Table) Projected Revenues and Market Share of Leading Suppliers of Other Cancer Vaccines 2012
• Issues and Trends
  • EARLY DETECTION AND SCREENING
    • (Table) Cancer Detection Tests
  • MONOCLONAL ANTIBODIES AND THERAPEUTIC VACCINES
  • POLITICAL AND SOCIAL PRESSURE
  • INSURANCE AND REIMBURSEMENT ISSUES
  • PERSONALIZED MEDICINE
  • PHARMACOGENOMICS
  • VACCINE STRATEGIES
  • NEW GENETIC TECHNIQUE
  • FUTURE GROWTH IN VACCINES
• Total Market Forecasts
  • OVERVIEW
  • TOTAL MARKET SIZE AND FORECAST
    • (Table) Cancer Vaccines Market by Cancer Type, 2007-2012
    • (Table) Share of the Cancer Vaccine by Vaccine Indication, 2012
  • COMPETITOR ANALYSIS
    • (Table) Suppliers/Developers of Vaccines by Cancer Type and Development Phase
    • (Table) Cancer Vaccine Trials, Distribution by Cancer Type, 2006
    • (Table) Cancer Vaccines: Cancer Vaccines in Development by Type and Phase
    • (Table) Cancer Vaccines: Cancer Vaccines in Developments by Phase, 2006
  • MARKET ANALYSIS
• Corporate Profiles
  • INTRODUCTION
  • ADVAXIS, INC.
  • ANTIGENICS, INC.
  • APHTON CORPORATION
  • AVAX TECHNOLOGIES, INC.
  • BIOMIRA, INC.
  • BIOVEST INTERNATIONAL, INC.
  • CELL GENESYS, INC.
  • DENDREON CORPORATION
  • FAVRILLE, INC.
  • GENEMAX CORPORATION
  • GENITOPE CORPORATION
  • GENZYME MOLECULAR ONCOLOGY
  • GERON CORPORATION
  • GLAXOSMITHKLINE PLC
  • IDM PHARMA, INC.
  • INTRACEL RESOURCES LLC
  • LARGE SCALE BIOLOGY CORPORATION
    • MEDAREX, INC.
    • MEDIMMUNE, INC.
    • MERCK & COMPANY, INC.
    • NORTHWEST BIOTHERAPEUTICS, INC.
    • OXFORD BIOMEDICA PLC
    • PHARMEXA GROUP
  • PROGENICS PHARMACEUTICALS, INC.
  • THERION BIOLOGICS CORPORATION
  • VICAL, INC.
  • YM BIOSCIENCES, INC.
• Company Directory